Skip to main content
. Author manuscript; available in PMC: 2010 Aug 12.
Published in final edited form as: J Thromb Haemost. 2008 Jul 24;6(10):1655–1662. doi: 10.1111/j.1538-7836.2008.03095.x

Table 3.

Thirty-day outcomes of clinical and pharmacogenetic algorithms in the validation cohorts.

Clinical (N=233) Genetic (N=179)
Mean PTTR (SD)* 61 (23.6) 68 (22.3)
Mean % time supratherapeutic (SD)* 11 (16) 8 (11.4)
Mean % time subtherapeutic (SD)* 28 (22.5) 24 (21.3)
Symptomatic adverse events (%) 7 (3.0) 1 (0.6)
     DVT 3 (1.3) 0 (0)
     PE 0 (0) 0 (0)
     Bleed 4 (1.7) 1 (0.6)

PTTR=Percent Time in Therapeutic Range. DVT=Deep Vein Thrombosis. PE=Pulmonary Embolism. Bleed=a hemorrhage requiring hospital treatment.

*

P < 0.05.